Print

Apricus Biosciences (APRI) Files Marketing Application for Vitaros(R) as a Treatment for Erectile Dysfunction in Switzerland  
7/19/2011 9:39:52 AM

SAN DIEGO, July 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today its filing of a marketing application for VitarosĀ® as a treatment for patients with erectile dysfunction ("ED") in Switzerland, with Swissmedic, the Swiss Agency for Therapeutic Products. "We are excited about making our third major filing for our flagship product, VitarosĀ® for the treatment of ED," said Dr. Bassam Damaj, Chairman, Chief Executive Officer and President of Apricus Bio.
//-->